Table 1.
Baseline characteristics of included randomized controlled trials.
| Studies | Intervention group (number) | Design | Sites | Age (years) | Female (%) | Mean STS score (%) | Prior MI (%) | Prior stroke (%) | NYHA III/IV symptoms | AF (%) | AVA (cm2) | Mean Gradient (mmHg) | Type of TAVR device | Follow-up duration (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DEDICATE-DZHK6 (2024)[10] | TAVR (7 0 1) | MCT | Germany | 74.3 | 44 | 1.8 | 5.2 | 6.1 | 46.2 | 28.9 | 0.8 | 46.5 | Balloon expandable (61.4 %), self-expanding (35.1 %) | 12 |
| SAVR (7 1 3) | 74.6 | 42.7 | 1.9 | 7.5 | 6.0 | 45.6 | 27.4 | 0.8 | 45.0 | |||||
| VIVA (2024)[11] | TAVR (77) | MCT | Canada, Europe & Brazil | 75.9 | 94.8 | 2.55 | − | − | 29.9 | 7.8 | 0.67 | 47.0 | Balloon expandable (40.8 %), self-expanding (59.2 %) | 24 |
| SAVR (74) | 75.1 | 90.5 | 2.43 | − | − | 32.4 | 18.9 | 0.74 | 49.0 | |||||
| PARTNER 3 (2023)[8] | TAVR (4 9 6) | MCT | USA, Austrailia, New Zealand | 73.3 | 32.5 | 1.9 | 5.7 | 3.4 | 31.2 | 15.7 | 0.8 | 49.4 | Balloon expandable SAPIEN 3 valve system | 60 |
| SAVR (4 5 4) | 73.6 | 28.9 | 1.9 | 5.8 | 5.1 | 23.8 | 18.8 | 0.8 | 48.3 | |||||
| EVOLUT Low Risk (2023)[9] | TAVR (7 3 0) | MCT | Northern America, Europe, Japan, Australia, New Zealand | 74.1 | 36.4 | 2.0 | 6.7 | 10.1 | 24.9 | 15.4 | 0.8 | 47.0 | Self-expanding CoreValve (3.6 %), Evolut R (74.1 %), Evolut PRO (22.3 %) | 48 |
| SAVR (6 8 4) | 73.7 | 34.1 | 1.9 | 4.8 | 12.0 | 28.2 | 14.4 | 0.8 | 46.6 | |||||
| UK TAVI (2022)[19] | TAVR (4 5 8) | MCT | United Kingdom | 81.0 | 46.1 | 2.6 | 9.5 | 5.7 | 40.3 | 24.0 | 0.7 | 43.1 | Balloon expandable (57.3 %), self-expanding (29.8 %) | 12 |
| SAVR (4 5 5) | 81.0 | 46.8 | 2.7 | 8.9 | 5.1 | 45.2 | 24.3 | 0.7 | 44.0 | |||||
| NOTION (2019)[17] | TAVR (1 4 5) | MCT MCT |
Denmark, Sweden | 79.2 | 46.2 | 2.9 | 5.5 | 16.6 | 48.6 | 27.8 | 0.7 | 43.4 | Self-expanding CoreValve bioprosthesis | 60 |
| SAVR (1 3 5) | 79.0 | 47.4 | 3.1 | 4.4 | 16.3 | 45.5 | 25.6 | 0.7 | 44.9 |